PapersFlow Research Brief
Lipid metabolism and disorders
Research Guide
What is Lipid metabolism and disorders?
Lipid metabolism and disorders encompass the genetic, pharmacologic, and physiological processes regulating lipids such as triglycerides and HDL cholesterol, including the roles of proteins like ANGPTL3, lipoprotein lipase, and GPIHBP1, with disorders manifesting as conditions like familial chylomicronemia syndrome, metabolic syndrome, and atherosclerosis.
The field includes 32,317 papers on lipid regulation by adipose tissue and its links to metabolic syndrome. Key focuses are triglyceride metabolism via ANGPTL3, ANGPTL4, and lipoprotein lipase, contributing to cardiovascular diseases. Growth data over the past 5 years is not available.
Topic Hierarchy
Research Sub-Topics
ANGPTL3 Inhibition Triglyceride Regulation
This sub-topic explores ANGPTL3's inhibition of lipoprotein lipase and its blockade for lowering triglycerides in hyperlipidemia. Researchers study monoclonal antibodies and genetic variants.
Familial Chylomicronemia Syndrome Genetics
This sub-topic covers genetic mutations in LPL, APOC2, and GPIHBP1 causing severe hypertriglyceridemia and pancreatitis risk. Researchers characterize phenotypes and genotype-phenotype correlations.
ANGPTL4 Role in Lipid Metabolism
This sub-topic investigates ANGPTL4's suppression of LPL in adipose tissue and its implications for fasting lipolysis. Researchers use knockout models and human GWAS data.
GPIHBP1 in Triglyceride Transport
This sub-topic examines GPIHBP1's role in anchoring LPL to capillaries for chylomicron lipolysis. Researchers study mutations causing hypertriglyceridemia.
Lipoprotein Lipase in Atherosclerosis
This sub-topic links LPL activity to remnant lipoprotein accumulation and plaque formation in cardiovascular disease. Researchers analyze functional variants and imaging studies.
Why It Matters
Lipid metabolism disorders drive cardiovascular diseases through elevated triglycerides and atherosclerosis, as seen in familial chylomicronemia syndrome. Grundy et al. (2005) in "Diagnosis and Management of the Metabolic Syndrome" provide AHA/NHLBI guidance for diagnosing and managing metabolic syndrome, which associates abdominal obesity, insulin resistance, and dyslipidemia, affecting heart disease risk in millions. Kleiner et al. (2005) in "Design and validation of a histological scoring system for nonalcoholic fatty liver disease" established a scoring system for NAFLD and NASH, enabling clinical trials that track liver damage from lipid accumulation, with applications in assessing progression in over 10,000 patients via the NASH Clinical Research Network. Teslovich et al. (2010) in "Biological, clinical and population relevance of 95 loci for blood lipids" identified 95 genetic loci influencing lipid levels, informing therapies targeting atherosclerosis in populations.
Reading Guide
Where to Start
"Diagnosis and Management of the Metabolic Syndrome" by Grundy et al. (2005), as it provides foundational AHA/NHLBI criteria and guidance linking lipid dysregulation to clinical cardiovascular risk.
Key Papers Explained
Grundy et al. (2005) in "Diagnosis and Management of the Metabolic Syndrome" establishes diagnostic criteria tying lipid disorders to heart disease. Kleiner et al. (2005) in "Design and validation of a histological scoring system for nonalcoholic fatty liver disease" builds by scoring lipid-induced liver pathology in metabolic contexts. Bäckhed et al. (2004) in "The gut microbiota as an environmental factor that regulates fat storage" extends to microbial influences on triglycerides, while Teslovich et al. (2010) in "Biological, clinical and population relevance of 95 loci for blood lipids" adds genetic loci; Giambartolomei et al. (2014) in "Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics" refines GWAS interpretation for lipid traits.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research centers on genetic loci for lipids from Teslovich et al. (2010) and colocalization methods in Giambartolomei et al. (2014), targeting ANGPTL3 and lipoprotein lipase in triglyceride disorders. No recent preprints or news available.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Diagnosis and Management of the Metabolic Syndrome | 2005 | Circulation | 11.6K | ✓ |
| 2 | Design and validation of a histological scoring system for non... | 2005 | Hepatology | 10.4K | ✕ |
| 3 | Revised 2003 consensus on diagnostic criteria and long-term he... | 2004 | Fertility and Sterility | 8.9K | ✕ |
| 4 | The gut microbiota as an environmental factor that regulates f... | 2004 | Proceedings of the Nat... | 6.1K | ✓ |
| 5 | Abdominal obesity and metabolic syndrome | 2006 | Nature | 4.2K | ✕ |
| 6 | Bayesian Test for Colocalisation between Pairs of Genetic Asso... | 2014 | PLoS Genetics | 4.2K | ✓ |
| 7 | Biological, clinical and population relevance of 95 loci for b... | 2010 | Nature | 3.6K | ✓ |
| 8 | Inflammatory Mechanisms in Obesity | 2011 | Annual Review of Immun... | 3.6K | ✕ |
| 9 | Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Asso... | 2001 | The Journal of Clinica... | 3.4K | ✓ |
| 10 | Genetic variation in PNPLA3 confers susceptibility to nonalcoh... | 2008 | Nature Genetics | 3.3K | ✓ |
Frequently Asked Questions
What is the metabolic syndrome?
The metabolic syndrome combines abdominal obesity, elevated triglycerides, low HDL cholesterol, hypertension, and hyperglycemia. Grundy et al. (2005) in "Diagnosis and Management of the Metabolic Syndrome" offer AHA/NHLBI criteria for its diagnosis and management to reduce cardiovascular risk. It links to insulin resistance and atherosclerosis.
How is nonalcoholic fatty liver disease assessed histologically?
NAFLD features hepatic steatosis without significant alcohol use, progressing to NASH. Kleiner et al. (2005) in "Design and validation of a histological scoring system for nonalcoholic fatty liver disease" validated a system scoring steatosis, inflammation, and ballooning for NASH Clinical Research Network trials. This enables standardized evaluation of lipid-related liver damage.
What role does gut microbiota play in lipid metabolism?
Gut microbiota regulates fat storage by processing dietary polysaccharides. Bäckhed et al. (2004) in "The gut microbiota as an environmental factor that regulates fat storage" showed germ-free mice gain less fat upon conventionalization, linking microbiota to energy harvest and obesity. This affects triglyceride levels and metabolic syndrome.
How do genetic loci influence blood lipids?
Genome-wide studies identify loci for lipid traits like triglycerides and HDL. Teslovich et al. (2010) in "Biological, clinical and population relevance of 95 loci for blood lipids" report 95 loci with population relevance for cardiovascular risk. Giambartolomei et al. (2014) in "Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics" enable colocalization analysis for causal variants in lipid GWAS.
What is the link between obesity and inflammation in lipid disorders?
Obesity induces inflammation in metabolic tissues, promoting insulin resistance. Gregor and Hotamışlıgil (2011) in "Inflammatory Mechanisms in Obesity" describe how adipose tissue inflammation drives type 2 diabetes and dyslipidemia. This connects to metabolic syndrome and atherosclerosis.
What genetic factor increases NAFLD susceptibility?
PNPLA3 genetic variation confers risk for nonalcoholic fatty liver disease. Romeo et al. (2008) in "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease" identified this association, linking it to hepatic lipid accumulation. It explains population differences in NAFLD prevalence.
Open Research Questions
- ? How do ANGPTL3 and lipoprotein lipase interactions precisely regulate triglyceride clearance in familial chylomicronemia syndrome?
- ? What are the causal genetic mechanisms linking GPIHBP1 variants to atherosclerosis progression?
- ? How does adipose tissue remodeling influence HDL cholesterol levels in metabolic syndrome?
- ? Which microbial pathways in the gut most directly modulate host lipid storage and obesity?
- ? How do colocalized genetic loci for lipids and cardiovascular traits inform targeted therapies?
Recent Trends
The field spans 32,317 works with no specified 5-year growth rate.
High-citation papers from 2001-2014 dominate, including 11,592 citations for Grundy et al. and 10,412 for Kleiner et al. (2005), emphasizing metabolic syndrome and NAFLD scoring.
2005Genetic studies like Teslovich et al. with 95 lipid loci and Romeo et al. (2008) on PNPLA3 persist as references.
2010No recent preprints or news reported.
Research Lipid metabolism and disorders with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Lipid metabolism and disorders with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers